Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

Blood (2023) 142 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2023-186722

Published: 2023

Journal Articles

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 292.

https://doi.org/10.1182/blood-2023-182967

Published: 2023

Journal Articles

BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

Alana L. Keller, Sarah E. Parzych, Lauren T. Reiman, Zachary J. Walker, Peter A. Forsberg, Daniel W. Sherbenou

Blood (2023) 142 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2023-187385

Published: 2023

Journal Articles

Activity of Selinexor As a Single Agent and Synergistic Activity with Approved/Investigational Myelofibrosis Therapies in Vitro

Marie E E Maloof, Stephen Wu, Andrea Ellero, Christopher J Walker, Steve Kye, Pietro Taverna

Blood (2023) 142 (Supplement 1): 6353.

https://doi.org/10.1182/blood-2023-180134

Published: 2023

Journal Articles

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 837.

https://doi.org/10.1182/blood-2023-181876

Published: 2023

Journal Articles

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Blood (2023) 142 (Supplement 1): 722.

https://doi.org/10.1182/blood-2023-185030

Published: 2023

Journal Articles

Selinexor Enhances Natural Killer Cell Function Against Multiple Myeloma Cells

Jack G Fisher, Amber DP Doyle, Lara V Graham, Francesco Forconi, Mark S Cragg, Christopher J Walker, Salim I Khakoo, Matthew D Blunt

Blood (2023) 142 (Supplement 1): 6599.

https://doi.org/10.1182/blood-2023-179744

Published: 2023

Journal Articles

Mechanisms and Therapeutic Strategies to Reverse TET2 Mutant Clonal Hematopoiesis and the Risk of MDS, AML, and Atherosclerotic Cardiovascular Disease

Nicole Prutsch, Amélie Vromman, Brittaney Leeper, Mengyu Chen, Shuning He, Siyang Ren, Christopher J. Walker, Mark W. Zimmerman, Mariana Janini Gomes, Eduardo J. Folco, Philipp J. Rauch, Prafulla C. Gokhale, Brian J. Abraham, Donna S. Neuberg, Benjamin L. Ebert, Peter Libby, A. Thomas Look

Blood (2023) 142 (Supplement 1): 937.

https://doi.org/10.1182/blood-2023-181149

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2023-187361

Published: 2023

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Blood (2022) 140 (Supplement 1): 7097–7099.

https://doi.org/10.1182/blood-2022-169072

Published: 2022

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt

Blood (2021) 138 (Supplement 1): 2411.

https://doi.org/10.1182/blood-2021-144836

Published: 2021

Journal Articles

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Michael P. Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J Carroll, Richard A. Larson, Jonathan E Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2021) 138 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2021-151610

Published: 2021

Journal Articles

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Zachary J Walker, Rachel N Steinmetz, Denis J Ohlstrom, Lauren T Reiman, Taylor S Mills, Beau M Idler, Brett M. Stevens, Eric Pietras, Daniel W. Sherbenou

Blood (2021) 138 (Supplement 1): 1604.

https://doi.org/10.1182/blood-2021-151953

Published: 2021

Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 457.

https://doi.org/10.1182/blood-2021-150522

Published: 2021

Journal Articles

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2021) 138 (Supplement 1): 221.

https://doi.org/10.1182/blood-2021-151072

Published: 2021

NARROW

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

Activity of Selinexor As a Single Agent and Synergistic Activity with Approved/Investigational Myelofibrosis Therapies in Vitro

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Selinexor Enhances Natural Killer Cell Function Against Multiple Myeloma Cells

Mechanisms and Therapeutic Strategies to Reverse TET2 Mutant Clonal Hematopoiesis and the Risk of MDS, AML, and Atherosclerotic Cardiovascular Disease

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only